Mizuho and BTIG positive on Haemonetics targets
Mizuho analyst Anthony Petrone maintained an Outperform rating for Haemonetics and raised the price target to $85 from $70. BTIG analyst Marie Thibault also expressed confidence, reiterating a Buy rating with a price target of $84.
*this image is generated using AI for illustrative purposes only.
Mizuho analyst Anthony Petrone has maintained an Outperform rating for Haemonetics and increased the stock's price target to $85 from $70, reflecting a more optimistic outlook on the company's performance potential. Separately, BTIG analyst Marie Thibault has reiterated a Buy rating on Haemonetics with a price target of $84.
Rating and Target Details
The adjustments come as firms evaluate Haemonetics' position in the market. Mizuho's new price target of $85 represents a significant increase from the previous $70 level, while BTIG maintains its stance at $84.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| Mizuho | Anthony Petrone | Outperform | $85 |
| BTIG | Marie Thibault | Buy | $84 |
What specific factors are driving the increased optimism for Haemonetics' performance potential?
How might Haemonetics' market position evolve in response to these analyst upgrades?
What are the potential risks or challenges that could impact Haemonetics' ability to meet these higher price targets?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
